Gensco® Leadership Team
Gensco® is a specialty pharmaceutical manufacturer specializing in development and commercialization of prescription topically-applied transdermal products. Our capabilities allow us to quickly launch products into significant niche markets. Our Leadership Team oversees organizational goals, strategic planning development, and overall decision making.
Medical Advisory Board
We currently have relationships with key medical advisors including:
James R. Andrews, MD
Orthopedic Surgeon Andrews Sports Medicine and Orthopedic Medicine.
Gary E. Myerson, MD
Rheumatologist Arthritis & Rheumatology Georgia, P.C.
Alesia Wagner, DO, FACOFP
Associate Professor, Primary Care Touro University College of Osteopathic Medicine
Marc Alan Brenner, DPM
Podiatrist The Institute for Diabetic Foot Research
Gensco® Pharma is committed to Better Science for Health.
Our resources are focused on innovative research, the development of superior quality medications and unique delivery systems. We are an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.
- AAP Issues Flu Vaccine Recommendations for 2018-2019 September 6, 2018 Articles, Industry - All children should receive the flu shot as soon as it is available: AAP [To more...
- A Case Study of Treatment of Recalcitrant Nonpressure Chronic Ulcers Using Astero Gel Topical Hydrogel with 4% Lidocaine for Autolytic Debridement and Pain Management November 13, 2017 Articles, Clinical, Featured, Research -
- An Exploratory, Single-blind Study to Evaluate Both the Onset of Anesthesia of LiDORx® in Patients Aged 18–88 Years November 9, 2017 Clinical, Research -
- Now Available Through Federal Supply Schedule (FSS) September 26, 2017 Featured, Press Release, Product Update - Contract #V797D-70219 The Only FDA-Approved Prescription Hydrogel and 4% Lidocaine HCl for Pain Associated with more...